US Clinical Data Highlight CERAMENTÂź G in Infection Prevention for Trauma Patients
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | HÀlsovÄrd |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem Àger bolaget?
All Àgardata du vill ha finns i Holdings!
BONESUPPORTâą, a leader in orthobiologics for the management of bone injuries, today announces the publication of the first US clinical case series describing a surgical technique and early outcomes using CERAMENT G during intramedullary nailing in patients with open fractures. Published in OTA International, the study offers practical insights for surgeons treating GustiloâAnderson Type II and III longâbone fractures.
The singleâcenter case series from HCA Florida Kendall Hospital, a Levelâ1 trauma center, reports on nine patients with open tibia, femur, or humerus fractures managed with CERAMENT G delivered through the FlowâFXâą 2âCANÂź device to support augmentation of an intramedullary nail and targeted gentamicin elution within the intramedullary canal. At an average followâup of 9.1 months, all patients achieved fracture union, with no fractureârelated infections, amputations, or reoperations for infection.
The authors conclude that augmentation of intramedullary nails with CERAMENT G may offer a timeâefficient, technically straightforward method for local antibiotic prophylaxis in highârisk open fractures.
âThis publication adds to the growing US clinical evidence base for CERAMENT G. Despite the small series, the results indicate that CERAMENT G provides reliable local antibiotic elution with the potential to help prevent infection, while also supporting bone healing when used for intramedullary nail augmentation in the management of complex open fractures,â said Torbjörn Sköld, CEO of BONESUPPORT.